Twitter | Pretraživanje | |
EBD Group
Speaking at 2020, , of gives an update the company's progress with its investigational medicine, OV101 (gaboxadol) for the treatment of Angelman syndrome and Fragile X syndrome >>
Reply Retweet Označi sa "sviđa mi se" More